Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785971 | 0.79 | TAAR1 (0.46) | TAAR1IDO1AGXTRIPK1ALDH1A1 | |
| SCHEMBL28123652 | 0.79 | CYP1A2 (0.50) | TAAR1IDO1AGXTRIPK1MAOB | |
| SCHEMBL1350580 | 0.77 | DNM1 (0.44) | SMN1; SMN2 | |
| SCHEMBL6787602 | 0.77 | TAAR1 (0.47) | TAAR1IDO1AGXT | |
| SCHEMBL1056081 | 0.76 | TAAR1 (0.59) | TAAR1IDO1AGXTDRD2SLC6A4 | |
| SCHEMBL6446590 | 0.76 | TP53 (0.41) | DRD2ALDH1A1 | |
| SCHEMBL6790593 | 0.76 | GLA (0.43) | DRD2SLC6A4SLC6A3CNR2 | |
| SCHEMBL12693653 | 0.74 | LPL (0.61) | TAAR1DRD2SLC6A4SLC6A3 | |
| Ethane SCHEMBL28237447 | 0.74 | TAAR1 (0.57) | TAAR1IDO1AGXTDRD2SLC6A4 | |
| SCHEMBL28123631 | 0.74 | DNM1 (0.46) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288612-B1 | GABAA RECEPTOR MODULATORS | GABATHER AB (SE) | 2015-07-29 | — | — | EP | disclosed |
| US-8809355-B2 | GABAA receptor modulators | INNOVATIONSPATENT SVERIGE AB (SE) | 2014-08-19 | — | — | US | disclosed |
| US-20110092525-A1 | GABAA RECEPTOR MODULATORS | GABATHER AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2288612-A1 | GABAA RECEPTOR MODULATORS | Forskarpatent i Syd AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009123537-A1 | GABAa RECEPTOR MODULATORS | FORSKARPATENT I SYD AB (SE) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092525-A1 | GABAA RECEPTOR MODULATORS | GABRA5, GABRA1, GABRA2 | TAAR1 119/4885IDO1 3597/4885AGXT 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.